News
ELDN
1.879
+2.68%
0.049
Weekly Report: what happened at ELDN last week (0219-0223)?
Weekly Report · 1d ago
Weekly Report: what happened at ELDN last week (0212-0216)?
Weekly Report · 02/19 11:58
Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Eledon Pharmaceuticals, Inc. Granted 42,500 restricted stock units and stock options to one employee to purchase 90,000 common shares. The RSUs and options were granted as inducements to the new employee entering employment with Eledon. The company's Compensation Committee granted the shares to the employee.
Barchart · 02/13 18:01
Weekly Report: what happened at ELDN last week (0205-0209)?
Weekly Report · 02/12 11:45
Weekly Report: what happened at ELDN last week (0129-0202)?
Weekly Report · 02/05 11:56
Weekly Report: what happened at ELDN last week (0122-0126)?
Weekly Report · 01/29 11:41
Weekly Report: what happened at ELDN last week (0115-0119)?
Weekly Report · 01/22 11:47
Weekly Report: what happened at ELDN last week (0108-0112)?
Weekly Report · 01/15 11:42
Weekly Report: what happened at ELDN last week (0101-0105)?
Weekly Report · 01/08 11:47
Eledon Pharmaceuticals reports recent business milestones
Eledon Pharmaceuticals reported updated data from ongoing Phase 1b trial in kidney transplantation. Tegoprubart treatment successfully prevented kidney transplant rejection and was generally safe and well-tolerated. The company expects to report updated interim clinical data from the trial by the first half of 2024.
Seeking Alpha · 01/05 07:35
Eledon Pharmaceuticals Provides Guidance For Anticipated Upcoming 2024 Milestones
Anticipated 2024 Milestones: Report updated clinical data from the ongoing Phase 1b trial of tegoprubart in kidney transplantation. Dose the first islet cell transplant participant for the treatment of type 1 diabetes. Complete enrollment in the Phase 2 BESTOW trial.
Benzinga · 01/04 21:44
Weekly Report: what happened at ELDN last week (1225-1229)?
Weekly Report · 01/01 11:39
Weekly Report: what happened at ELDN last week (1218-1222)?
Weekly Report · 12/25/2023 11:54
Weekly Report: what happened at ELDN last week (1211-1215)?
Weekly Report · 12/18/2023 12:01
Weekly Report: what happened at ELDN last week (1204-1208)?
Weekly Report · 12/11/2023 11:55
Eledon Pharmaceuticals: A Strong Buy on Promising Pipeline and Market Potential
Lifesci capital analyst rami katkhuda has given eledon pharmaceuticals a buy rating and a $9.00 price target. Lifesci remains neutral on the stock and has a positive view of the company's potential. The company is developing a cd40l inhibitor with potential to treat multiple sclerosis and type 1 diabetes.
TipRanks · 12/07/2023 22:35
Weekly Report: what happened at ELDN last week (1127-1201)?
Weekly Report · 12/04/2023 11:54
Weekly Report: what happened at ELDN last week (1120-1124)?
Weekly Report · 11/27/2023 11:45
Weekly Report: what happened at ELDN last week (1113-1117)?
Weekly Report · 11/20/2023 11:43
More
Webull provides a variety of real-time ELDN stock news. You can receive the latest news about Eledon Pharmaceuticals Inc through multiple platforms. This information may help you make smarter investment decisions.
About ELDN
Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing life-changing, targeted medicines for persons requiring an organ or cell-based transplant, living with autoimmune disease, or living with amyotrophic lateral sclerosis (ALS). The Company's lead compound in development is tegoprubart, an IgG1, an anti-CD40L antibody with a high affinity for CD40 Ligand (CD40L, also called CD154). Tegoprubart is engineered to potentially both improve safety and provides pharmacokinetic, pharmacodynamic, and dosing advantages. CD40L is primarily expressed on activated CD4+ T cells, platelets, and endothelial cells while the CD40 receptor is constitutively expressed on antigen-presenting cells, such as macrophages and dendritic cells, as well as B cells.